The use of P53, PTEN, and C-erbB-2 to differentiate uterine serous papillary carcinoma from endometrioid endometrial carcinoma

International Journal of Gynecological Cancer

Volumn 14, Issue 5, 2004, Pages 938-946

  MacWhinnie, N ^a   Monaghan, H ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

C erbB 2; P53; PTEN; Uterine serous papillary carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN ANTIBODY; PROTEIN P53;

ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE SEROUS PAPILLARY CARCINOMA; UTERUS CARCINOMA;

CARCINOMA, ENDOMETRIOID; CARCINOMA, PAPILLARY; DIAGNOSIS, DIFFERENTIAL; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORIC MONOESTER HYDROLASES; PTEN PHOSPHOHYDROLASE; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 4544219785     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1048-891X.2004.14533.x     Document Type: Article

References (32)

1. Creasman WT, Odicino F, Maisonneuve P et al. Carcinoma of the corpus uteri. J Epidemiol Biostat 2001;6: 45-86.
2. Stevens A, Lowe J. Pathology. St Louis: Mosby, 1999, 371-4.
3. Burton JL, Wells M. Recent advances in the histopathology and molecular pathology of carcinoma of the endometrium. Histopathology 1998;33:297-303.
4. Santin AD. Her2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed? Gynaecol Oncol 2003;88:263-5.
5. Santin AD, Bellone S, Gokden M et al. Overexpression of Her-2/neu in uterine serous papillary cancer. Clin Cancer Res 2002;8:1271-9.
6. Hendrickson M, Martinez A, Ross J, Kempson R, Eifel P. Uterine papillary serous carcinoma, a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982;6:93-107.
7. Moll UM, Chalas E, Auguste M, Meaney D, Chumas J. Uterine papillary serous carcinoma evolves via a P53 driven pathway. Hum Pathol 1996;27:1295-300.
8. Zheng W, Khurana R, Farahmand S, Wang Y, Zhang Z-F, Felix JC. P53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma, precursor of uterine papillary serous carcinoma. Am J Surg Pathol 1998;22:1463-73.
9. Spiegel GW. Endometrial carcinoma in situ in postmenopausal women. Am J Surg Pathol 1995;19:417-32.
10. Lim P, Al Kushi A, Gilks B, Wong F, Aquino-Parsons C. Early stage uterine serous papillary carcinoma of the endometrium, effect of whole abdominal radiotherapy and pathologic parameters on outcome. Cancer 2001;91:752-7.
11. Vogelstein B, Kanzler KW. P53 function and dysfunction. Cell 1992;70:523-6.
12. Cherchi PL, Marras V, Capobianco G et al. Prognostic value of P53, c-erbB-2 and MIB1 in endometrial carcinoma. Eur J Gynaecol Oncol 2001;22:451-3.
13. Czerwenka K, Lu Y, Heuss F. Amplification and Expression of the c-erbB-2 oncogene in normal, hyperplastic and malignant endometria. Eur J Gynaecol Oncol 1995;14:98-106.
14. Mutter GL, Lin MC, Fitzgerald JT et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Nat Cancer Inst 2000;92:924-30.
15. Tashiro H, Blazes MS, Wu R et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynaecological malignancies. Cancer Res 1997; 57:3935-40.
16. King SA, Adas AA, LiVolsi VA et al. Expression and mutation analysis of the P53 gene in uterine papillary serous carcinoma. Cancer 1995;75:2700-5.
17. Ohkouchi T, Sakuragi N, Watari H et al. Prognostic significance of Bcl-2, P53 overexpression and lymph node metastasis in surgically staged endometrial carcinoma. Am J Obstet Gynecol 2002;185:353-9.
18. Matias-Guiu X, Catasus L, Bussaglia E et al. Molecular Pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001;32:569-77.
19. Sun H, Lesche R, Li D, Wu H. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol3,4,5,-triphosphate and akt/protein kinase B signalling pathway. Cell Biol 1999;96:6199-204.
20. Latta E, Chapman WB. PTEN mutations and evolving concepts in endometrial neoplasia. Curr Opin Obstet Gynecol 2002;14:59-65.
21. Li J, Yen C, Liaw D et al. PTEN, a putative protein tyrosine phosphatases gene mutated in human brain, breast and prostate cancer. Science 1997;275:1943-7.
22. Wen S, Stolarov J, Myers MP et al. PTEN controls tumour-induced Angiogenesis. Proc Natl Acad Sci USA 2001;98:4622-7.
23. Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 2001;8:11-31.
24. Mostcatello DK, Holgado-Madruga M, Godwin AK et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumours. Cancer Res 1995;55:5536-9.
25. Cirisano FD, Karlan BY. The role of the Her-2/neu oncogene in gynaecological cancers. J Soc Gynecol Investig 1996;3:99-105.
26. Hoos A, Cordon-Cardo C. Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest 2001;81:1331-8.
27. Sherman ME, Bur ME, Kurman RJ. P53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995;26:1268-74.
28. Halperin R, Zehavi S, Habler L, Hadas E, Bukovsky I, Schneider D. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of the endometrium. Eur J Gynaecol Oncol 2001;22:122-6.
29. Kounelis S, Kapranos N, Kouri E, Coppola D, Papadaki H, Jones MN. Immunohistochemical profile of endometrial adenocarcinoma. a study of 61 cases and review of the literature. Mod Pathol 2000;13:379-88.
30. Athanassiadou P, Petrekakou E, Liossi A et al. Prognostic significance of P53, bcl2 and EGFR in carcinoma of the endometrium. Acta Cytol 1999;43:1039-44.
31. Demopoulos RI, Mesia AF, Mittal K, Vamvakas E. Immunohistochemical comparison of uterine serous papillary and papillary endometrioid carcinoma: clues to pathogenesis. Int J Gynecol Pathol 1999;18:233-7.
32. Risinger JI, Hayes AK, Berchuck A, Barrett JC. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 1997;57:4736-8.